i think lucly bloke makes some good points and if revenue doesnt...

i think lucly bloke makes some good points and if revenue doesnt rise rapidly (which is entirely possible given it is a slow process to convert surgeons initially until a critical mass of momentum is reqched and it is accepted as a standard of care in a few years) then shareholders could get impatient and sell it off.

its a great technology long term but so is mesoblast msb and look what has happened over several years as its tried to move from an exciting technology to late phase trials - these take years and are very capital intensive so lots of cash burn.

the good news for pnv is that devices and implants tend to be fda/ ce approved faster than drugs without needing large phase 3 rct’s, but the bad news is you dont get the rapid uptake of a new device in the same way you get rapid uptake of a new drug, because surgeons need to take the time to feel comfortable with how and when to use the new device/ material.

this is quite a big step to change how you do surgery compared to just writing a different name on a script.

i can say this as a surgeon myself.

anyway i love the pnv technology but it will take a long time just as it has already to teqxh its full potential.

in hernias for example, we use other biologic porcine meshes such as strattice and the pnv matrix will need to be proven to have durable results in large trials with followup over several years before it is used for hernias, which is different to the low hanging fruit area of need that is burns/ necrotising fasciitis/ trauma etc.

im happy sitting on my pnv but would probably sell some if it runs to 60+ again on good sales figures but without any major catalyst to cause me to teassess my valuation.